HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Compass Therapeutics (CMPX) with a maintained price target of $10.
March 21, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Compass Therapeutics maintains a Buy rating and a $10 price target from HC Wainwright & Co.
The reiteration of a Buy rating and a $10 price target by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could positively influence the stock price of Compass Therapeutics in the short term. The specific mention of the company and the reaffirmation of the price target suggest a strong belief in the company's potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100